For the quarter ended March 2026, Biogen Inc. (BIIB Quick QuoteBIIB - Free Report) reported revenue of $2.48 billion, up 1.9% over the same period last year. EPS came in at $3.57, compared to $3.02 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $2.25 billion, representing a surprise of +10.12%. The company delivered an EPS surprise of +20.87%, with the consensus EPS estimate being $2.95.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product- Multiple Sclerosis (MS)- Interferon- Rest of world: $94.7 million versus $82.84 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +1.2% change.
• Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States: $31.4 million versus the 22-analyst average estimate of $33.59 million. The reported number represents a year-over-year change of -21.1%.
• Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States: $132.8 million versus $130.06 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change.
• Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Rest of world: $78.1 million compared to the $76.98 million average estimate based on 22 analysts. The reported number represents a change of -53% year over year.
• Revenue- Anti-CD20 therapeutic programs: $419.1 million versus $428 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
• Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $441.5 million versus $358.98 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a +15.7% change.
• Alzheimer's collaboration revenue: $59.5 million versus $55.76 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a +80.3% change.
• Revenue- Product- Rare Disease- SKYCLARYS- Total: $150.7 million compared to the $137.3 million average estimate based on 24 analysts. The reported number represents a change of +21.6% year over year.
• Revenue- Product- Rare Disease- SPINRAZA- Total: $374 million compared to the $378.79 million average estimate based on 24 analysts. The reported number represents a change of -11.8% year over year.
• Revenue- Product- Biosimilars- Total: $182.2 million versus $161.59 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +0.8% change.
• Revenue- Product, net: $1.75 billion versus $1.61 billion estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +1.5% change.
• Revenue- Contract manufacturing, royalty and other revenue: $246.9 million compared to the $153.29 million average estimate based on 23 analysts.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have remained unchanged over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.